Compare NODK & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | EOLS |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.8M | 284.3M |
| IPO Year | 2016 | 2018 |
| Metric | NODK | EOLS |
|---|---|---|
| Price | $12.48 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 20.9K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | $285,050,000.00 | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $12.01 | $3.86 |
| 52 Week High | $14.70 | $12.28 |
| Indicator | NODK | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 37.79 |
| Support Level | $12.39 | N/A |
| Resistance Level | $13.70 | $4.99 |
| Average True Range (ATR) | 0.46 | 0.23 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 32.52 | 12.83 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.